ALXN1210 Versus Eculizumab in Adult Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) currently Treated With Eculizumab

Trial Identifier: ALXN1210-PNH-302
Sponsor: Alexion Pharmaceuticals, Inc.
Start Date: May 2017
Primary Completion Date: February 2022
Study Completion Date: February 2022
Condition: Heart, Blood & Circulatory - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
French (France) Translation
English (Canada) Translation
German (Germany) Translation
Dutch (Netherlands)
English (United Kingdom)
French (Canada) Translation
English (Australia)

Trial Locations

Country Location
AU Canberra, AU, 2605
AU Kogarah, AU, 2217
AU Liverpool, AU, 2170
AU Melbourne, AU, 3000
AU Woolloongabba, AU, 4102
CA, ON Toronto, ON, CA, M4N 3M5
CA, Ontario Toronto, Ontario, CA, M5G 2C4
CA, QC Montreal, QC, CA, H1T 2M4
DE Aachen, DE, 52074
DE Essen, DE, 45147
DE Ulm, DE, 89081
ES Barcelona, ES, 8036
ES Madrid, ES, 28040
ES Majadahonda, ES, 28220
FR Amiens, FR, 80054
FR La Tronche, FR, 38043
FR Marseille, FR, 13273
FR Nice, FR, 06200
FR Paris, FR, 75475
FR Pierre-Benite, FR, 69495
FR Saint-Priest-En-Jarez, FR, 42270
FR Strasbourg, FR, 67091
GB Airdrie, GB, ML6 0JS
GB Leeds, GB, LS9 7TF
GB London, GB, SE5 9NU
IT Firenze, IT, 50134
IT Milano, IT, 20122
IT Napoli, IT, 80131
IT Torino, IT, 10126
IT Vicenza, IT, 36100
JP Fukushima-shi, JP, 960-1295
JP Kanazawa-shi, JP, 920-8641
JP Shinagawa-ku, JP, 141-0022
JP Suita-shi, JP, 565-0871
JP Suwa-shi, JP, 392-8510
KR Bucheon-si, KR, 14584
KR Daegu, KR, 42415
KR Daejeon, KR, 35015
KR Incheon, KR, 21565
KR Seoul, KR, 3722
KR Seoul, KR, 06351
KR Seoul, KR, 6591
KR Seoul, KR, 03080
KR Suwon, KR, 16247
NL Maastricht, NL, 6202 AZ
NL Nijmegen, NL, 6525 GA
US, CA Duarte, CA, US, 91010
US, CA Los Angeles, CA, US, 90089
US, MD Baltimore, MD, US, 21205
US, MI Detroit, MI, US, 48202
US, NY Bronx, NY, US, 10467